We are live on
!
Find out more
CS
Candriam SCA Portfolio holdings
AUM
$19.3B
1-Year Est. Return
39.18%
This Fund
S&P 500
This Quarter
Est. Return
+4.05%
1 Year Est. Return
+39.18%
3 Year Est. Return
+109.85%
5 Year Est. Return
+149.31%
10 Year Est. Return
+617.16%
AUM
$6.32B
AUM Growth
+$456M
(+7.8%)
Cap. Flow
+$224M
Cap. Flow
% of AUM
3.55%
Top 10 Holdings %
Top 10 Hldgs %
17.62%
Holding
844
New
72
Increased
349
Reduced
257
Closed
60
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Broadcom
AVGO
|
+$37.6M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$29.3M |
| 3 |
Biogen
BIIB
|
+$27.4M |
| 4 |
Home Depot
HD
|
+$22.7M |
| 5 |
Cisco
CSCO
|
+$21.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan Chase
JPM
|
+$23.6M |
| 2 |
TJX Companies
TJX
|
+$19.3M |
| 3 |
FedEx
FDX
|
+$16.4M |
| 4 |
Intuit
INTU
|
+$14.7M |
| 5 |
Corning
GLW
|
+$13.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.18% |
| 2 | Technology | 17.19% |
| 3 | Financials | 12.85% |
| 4 | Consumer Discretionary | 10.2% |
| 5 | Communication Services | 8.65% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GG
251
DELISTED
Goldcorp Inc
GG
| $6.33M | 0.1% |
461,723
-3,056
| -0.7% | -$42.4K |
|
|
CBAY
252
DELISTED
Cymabay Therapeutics
CBAY
| $6.31M | 0.1% |
470,000
+225,000
| +92% | +$2.82M |
|
253
Ross Stores
ROST
$76.6B
| $6.27M | 0.1% |
73,949
+42,213
| +133% | +$3.44M |
|
254
Yum China
YUMC
$14.9B
| $6.23M | 0.1% |
162,000
-90,500
| -36% | -$3.59M |
|
255
Puma Biotechnology
PBYI
$406M
| $6.21M | 0.1% |
105,000
+37,000
| +54% | +$2.14M |
|
|
SPPI
256
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
| $6.17M | 0.1% |
294,500
+109,500
| +59% | +$2.03M |
|
257
Zebra Technologies
ZBRA
$12.4B
| $6.14M | 0.1% |
42,874
+22,111
| +106% | +$3.26M |
|
258
Suncor Energy
SU
$77.7B
| $6.04M | 0.1% |
148,461
+10,436
| +8% | +$407K |
|
259
PVH
PVH
$3.71B
| $5.92M | 0.09% |
39,520
-6,638
| -14% | -$1.04M |
|
260
Newmont
NEM
$98.2B
| $5.9M | 0.09% |
156,494
-906
| -0.6% | -$35.6K |
|
261
Bio-Rad Laboratories Class A
BIO
$8.42B
| $5.89M | 0.09% |
20,400
+2,900
| +17% | +$801K |
|
262
APA Corp
APA
$12.8B
| $5.84M | 0.09% |
124,899
-126,483
| -50% | -$5.25M |
|
|
MRSH
263
Marsh
MRSH
$86.3B
| $5.82M | 0.09% |
70,990
+6,829
| +11% | +$557K |
|
264
Veeco
VECO
$3.15B
| $5.81M | 0.09% |
407,647
+63,188
| +18% | +$1.05M |
|
265
Kinder Morgan
KMI
$73.1B
| $5.81M | 0.09% |
328,605
-120,334
| -27% | -$1.97M |
|
266
Magna International
MGA
$17.9B
| $5.78M | 0.09% |
99,437
-98,300
| -50% | -$6.1M |
|
|
ESRX
267
DELISTED
Express Scripts Holding Company
ESRX
| $5.68M | 0.09% |
73,562
-128,510
| -64% | -$9.64M |
|
268
S&P Global
SPGI
$126B
| $5.68M | 0.09% |
27,847
-425
| -2% | -$84K |
|
269
TG Therapeutics
TGTX
$8.58B
| $5.59M | 0.09% |
425,000
+65,000
| +18% | +$894K |
|
270
Exelixis
EXEL
$13.9B
| $5.58M | 0.09% |
259,500
+36,000
| +16% | +$744K |
|
|
SCHW
271
Charles Schwab
SCHW
$177B
| $5.53M | 0.09% |
108,248
+4,092
| +4% | +$227K |
|
272
Blackrock
BLK
$164B
| $5.52M | 0.09% |
11,055
-163
| -1% | -$86.1K |
|
273
PNC Financial Services
PNC
$100B
| $5.51M | 0.09% |
40,761
-3,334
| -8% | -$486K |
|
|
PTLA
274
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $5.5M | 0.09% |
145,700
+25,200
| +21% | +$964K |
|
275
Omnicom Group
OMC
$22.7B
| $5.44M | 0.09% |
71,292
-69,809
| -49% | -$5.16M |
|
Similar funds
PCM
A
MGP
LF
SOMRS
BPA
MIM
Candriam SCA's Q2 2018 Portfolio in Review
As of Q2 2018, Candriam SCA held 844 positions worth $6.32B, up 7.8% from $5.86B the previous quarter. Its ten largest holdings account for 18% of the portfolio.
Candriam SCA deployed $224M of net new capital in Q2 2018, opening 72 new positions and adding to 349 existing holdings. Its largest new stake was Broadcom: 1,532,450 shares worth $37.2M.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, up from 23% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was JPMorgan Chase, an estimated $23.6M trimmed.
- Candriam SCA's largest Q2 2018 buy was Broadcom: 1,532,450 shares worth $37.2M.
- Candriam SCA added most to Bristol-Myers Squibb in Q2 2018, an estimated $29.3M increase.
- Candriam SCA's biggest Q2 2018 reduction was JPMorgan Chase, cutting an estimated $23.6M.
- Candriam SCA fully exited Monsanto Co in Q2 2018, selling an estimated $11.5M.
- Candriam SCA's ten largest holdings make up 18% of its $6.32B portfolio in Q2 2018.
- Candriam SCA opened 72 new positions and closed 60 in Q2 2018.
- Candriam SCA's portfolio value rose 7.8% quarter-over-quarter to $6.32B.
Based on Candriam SCA's 13F filing for Q2 2018, filed 14 Aug 2018.